NRX Pharmaceuticals Q1 EPS $(0.74) Misses $(0.37) Estimate

NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.37) by 100 percent. This is a 53.75 percent increase over losses of

Benzinga15:37

Oppenheimer Reiterates Outperform on Mind Medicine, Lowers Price Target to $20

Oppenheimer analyst Francois Brisebois reiterates Mind Medicine (NASDAQ:MNMD) with a Outperform and lowers the price target from $29 to $20.

BenzingaMay 13 07:34

Seritage Growth Properties Posts Q1 Loss, Joins Fortrea Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Monday.Shares of Seritage Growth Properties (NYSE:SRG) fell sharply in today's pre-market trading after

BenzingaMay 13 07:31

Compass Pathways Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 1357.99% HC Wainwright & Co. → $120 Reiterates Buy → Buy 04/30/2024 — Cantor Fitzgerald Reiter

BenzingaMay 13 04:44

HC Wainwright & Co. Maintains Buy on Mind Medicine, Lowers Price Target to $35

HC Wainwright & Co. analyst Patrick Trucchio maintains Mind Medicine (NASDAQ:MNMD) with a Buy and lowers the price target from $75 to $35.

BenzingaMay 10 14:39

Mind Medicine Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 280.43% HC Wainwright & Co. $75 → $35 Maintains Buy 04/15/2024 117.39% Leerink Partners → $20 I

BenzingaMay 10 14:37